Month: March 2022

GM 2021 Supplier of the Year Award Gentex Corporation was recently recognized by General Motors as a 2021 Supplier of the Year.ZEELAND, Mich., March 29, 2022 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ:GNTX) was recently recognized by General Motors as a 2021 Supplier of the Year during GM’s 30th annual Supplier of the Year awards ceremony in Phoenix, Arizona. GM’s Supplier of the Year award recognizes global suppliers that distinguish themselves by exceeding GM’s requirements – in turn providing GM customers with innovative technologies — and are among the highest quality in the automotive industry. This year, GM recognized 134 suppliers from 16 countries with the Supplier of the Year distinction. Gentex is a leading supplier of digital vision, connected car, and dimmable glass technologies for the global automotive industry....

Suominen Corporation’s press release on March 29, 2022 at 3:00 p.m. EEST Suominen launches a carbon neutral nonwoven, BIOLACE® Zero. BIOLACE® Zero is an excellent product for many kinds of wiping applications like baby, personal care, and household wipes. It has excellent wet and dry strength and it’s very soft. It is made of 100% cellulosic lyocell fibers and the product is 100% biodegradable, compostable and plastic free. BIOLACE® Zero utilizes VEOCEL™ Lyocell fibers from Suominen´s long-term partner Lenzing. BIOLACE® Zero is made of 100% carbon neutral VEOCEL™ Lyocell fibers. “We are very excited to introduce BIOLACE® Zero, which is not just Suominen´s first carbon neutral product, but also one of the first carbon neutral nonwovens on the market. BIOLACE® Zero will be available as part of Suominen’s sustainable product portfolio”,...

Lundin Energy AB (Lundin Energy) announces that the first instalment of the proposed quarterly cash dividend of USD 0.5625 per share will amount to SEK 5.30 per share, with a total amount of MSEK 1,508, corresponding to approximately MUSD 160. The proposed quarterly cash dividend remains subject to approval by the 2022 Annual General Meeting (AGM) that will be held on 31 March 2022. Information about the first instalment of the proposed quarterly cash dividend:Amount per share(SEK) Total dividend amount (MSEK) Ex-dividend date Record date Expected payment date5.30 1,508 1 April 2022 4 April 2022 7 April 2022The Board of Directors has proposed to the 2022 AGM a quarterly cash dividend for 2021 of USD 0.5625 per share, corresponding to MUSD 160 (rounded off) per quarter. According to the proposal, before payment, each quarterly...

Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds SAWC to Take Place in Phoenix, Arizona on April 6-10, 2022 YAVNE, Israel, March 29, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced a poster and oral presentation of its EscharEx® clinical data at the 35th Symposium on Advanced Wound Care (SAWC) Spring Conference taking place in Phoenix, Arizona on April 6-10, 2022 (Home | SAWC Spring). The oral presentation, titled: “Introduction to EscharEx: An Innovative Enzymatic Solution for the Debridement of Hard to Heal Wounds,” will be moderated by Vickie R. Driver, DPM, MS, FACFAS FAAWC (University of Virginia and Inova Healthcare) and will feature, John C. Lantis, M.D....

HENDERSON, NV, March 29, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Grove, Inc. (NASDAQ:GRVI) (“Grove” or the “Company”),Grove Inc., today announced that it has completed the first stage of its previously authorized program to repurchase up to 1 million shares of its outstanding common stock through both the use of the Company’s 10b5-1 plan and privately negotiated transactions.  The Company repurchased 467,765 shares at an average cost of approximately $4.22 per common share or $1,974,896. These repurchases were made as part of the company’s repurchase program, which was announced on October 19, 2021. Grove will continue to review the authorized program and may repurchase up to an additional 500,000 shares.  “Grove continues to generate strong revenue growth, positive cash flow from operations...

Fully understanding the customer’s reality will guide decision-making as FuelPositive prepares for commercialization TORONTO, March 29, 2022 (GLOBE NEWSWIRE) — FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) is pleased to announce two key appointments focused on fully understanding its customers as it nears market entry. Pollara Strategic Insights has been appointed FuelPositive’s market research partner. As well, Leith Deacon, an Associate Professor and researcher from the University of Guelph, has been appointed as an Advisor, helping to guide the Company’s market research efforts. “We have identified the farming community in Canada as our first customer for our on-site green ammonia production system. That means we need to learn everything we can about farmers. We already know they are...

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) — Reservoir Media, Inc. (NASDAQ: RSVR) (“Reservoir” or the “Company”), an award-winning independent music company, today announced a new deal for the catalog of the late lyricist Larry Kusik, best known for his collaborations on theme songs from blockbuster films like The Godfather and Romeo and Juliet. Kusik was a prolific lyricist whose works can be heard in some of the most iconic films released during the 1960s and 1970s. He notably penned the lyrics for “Speak Softly Love,” the lyricized theme from 3x-Academy Award-winning film The Godfather, which celebrated its 50th anniversary this month and is widely recognized as one of the greatest films of all time. “Speak Softly Love” won Kusik an ASCAP award and was recorded by several artists, with Andy Williams’ version climbing to #34 on...

IRVINE, Calif. and MIAMI, March 29, 2022 (GLOBE NEWSWIRE) — CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System will be used by Focalyx Technologies, developer of image-guided fusion target devices, to conduct a 20-patient, Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.” The study will utilize the Focalyx® Fusion medical device for treatment planning, image fusion, real-time image guidance during treatment, and CLS’s TRANBERG® Thermal Therapy System for high-precision, focal laser ablation. Other instruments will be used during the procedure as well. The study will be conducted by Urological Research Network, LLC, a Florida-based, not-for-profit clinical research organization. “CLS...

Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as a poster at upcoming AACR Annual Meeting in April 2022 Anticipate initiating Phase 2 studies of VIP152 in 2H2022 IND filing for small molecule drug conjugate (SMDC) candidate, VIP236, in solid tumors on-target for 2H2022 Approved for German government research allowance of up to EUR 6 million Expected cash runway through 2023 PALO ALTO, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a corporate update. “We...

Study results demonstrate lead compounds increase GCase protein levels, activity and co-localization in the lysosome, and decrease toxic substrate accumulation BETHESDA, Md., March 29, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today presented new pre-clinical data from its Gaucher Disease (GD) program. The results were highlighted in a poster presentation at the 2022 Glycolipid and Sphingolipid Biology GRC being held March 27 – April 1, 2022, in Castelvecchio Pascoli, Italy. The data show that the tested compounds increase the levels and activity of the beta-glucocerebrosidase (GCase) protein, increase co-localization of...